Leadiant Biosciences, Inc.

Chiesi Farmaceutici S.p.A. is actively expanding its rare disease business in Japan through a subsidiary established there in 2022 and as part of the family-owned Italian firm's global push into this

Pfizer Inc. has five of the 27 Part B drugs subject to Medicare price inflation rebates for the first time under the Inflation Reduction Act, according to a list compiled by the Centers for Medicare

The independent drug bulletin, Prescrire, has attacked the EU’s drug regulatory system, claiming that it “continues to take the side of companies” and fails to sufficiently protect patients from poten

A Dutch university hospital has restarted production of its own low-cost version of Leadiant Biosciences' orphan drug, chenodeoxycholic acid (CDCA), to address what it says is the unreasonably high